Bal Pharma's financial performance shows a mixed trend in sales and profit growth.

Inconsistent Sales Growth

Sales growth has been erratic. Sales growth averaged 5.19% from 2014-2016, 4.91% from 2017-2019. A significant increase to 25.23% was observed during 2020-2022, followed by a drop to 8.17% in 2023 and a slight recovery to 11.50% in 2024. The compounded sales growth shows a concerning trend with the TTM at just 1%.

Profit Growth

Profit growth has been highly volatile. From 2014-2016, the company experienced an average decline of -16.23%, followed by a substantial recovery with an average growth of 119.59% from 2017-2019. This growth decelerated to 8.79% during 2020-2022, with a sharp decline of -54.21% in 2023 before rebounding to 183.21% in 2024. The recent TTM compounded profit growth is strong at 138%.

The capital efficiency and returns of Bal Pharma present a mixed picture as ROCE and ROE are positive but do not indicate outstanding performance.

Return on Capital Employed (ROCE)

ROCE has shown a slight improvement over the years but remains modest. The average ROCE was 8.33% from 2014-2016, 7.67% from 2017-2019 and 8% from 2020-2022. It increased to 10% in 2023 and 12% in 2024, indicating better capital utilization recently.

Return on Equity (ROE)

ROE has fluctuated. The average ROE was 2% from 2017-2019 and increased to 8% from 2020-2022. It decreased to 4% in 2023 but rebounded to 11% in 2024. These values suggest that shareholder funds are yielding moderate returns, with recent improvements.

Bal Pharma's financial health exhibits concerning trends related to debt management.

Increasing Debt Levels

Borrowings have generally increased over the years. Debt levels rose from ₹93 Cr in 2017 to ₹124 Cr in 2019, decreased to ₹104 Cr in 2022, but have since increased to ₹155 Cr by September 2024. This indicates increasing financial leverage.

Interest Coverage Ratio

The interest coverage ratio, calculated as Operating Profit divided by Interest, reflects the company's ability to pay interest expenses from its operating profit. The ratio has fluctuated, with a concerning low of 0.38 in 2020. Although it has improved since then, the fluctuating coverage indicates potential vulnerability in consistently meeting interest obligations.

The shareholding and ownership structure of Bal Pharma indicates a reasonably stable ownership with a moderate promoter holding.

Promoter Holding

The promoter holding has generally increased over the years, indicating increased confidence by the promoters. The promoter holding has increased from 44.35% in March 2017 to 50.87% in September 2024.

Institutional Holding

FII holding is minimal and has remained consistently low.

The quarterly results of Bal Pharma indicate some volatility in segment performance, as evidenced by fluctuating sales and profit figures.

Quarterly Sales and Profit Variability

There are fluctuations in both sales and net profit. Sales have varied from ₹73.69 Cr to ₹94.63 Cr, while net profit has seen more significant swings, ranging from ₹0.26 Cr to ₹5.53 Cr.

The data does not clearly quantify foreign exchange exposure, however, interest rate exposure is evident. Bal Pharma's financial statements indicate an exposure to interest rate fluctuations through its borrowings.

Interest Expense Trends

Interest expenses have increased from ₹12 Cr in 2021 to ₹15 Cr in 2024. This rise suggests a growing impact of interest rates on the company's profitability.

While specific figures for regulatory compliance costs are not explicitly detailed, the trend can be inferred from the general administrative and operational expenses reported in the quarterly results.

Operating Expenses Analysis

Operating expenses have shown some variability. Expenses have ranged from ₹66.00 Cr to ₹85.03 Cr, indicating fluctuations in operational costs, which may include regulatory compliance.